Stock AGEN AGENUS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Agenus Inc.

Equities

AGEN

US00847G8042

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
15.69 USD +3.84% Intraday chart for Agenus Inc. +15.20% -5.24%
May. 16 Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer CI
May. 07 Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
BU
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
BU
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
BU
Agenus: Q1 Earnings Snapshot
AQ
Agenus Reports First Quarter 2024 Results
BU
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
BU
Agenus Inc. - Botensilimab, Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
AQ
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
BU
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
BU
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
AQ
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
BU
Agenus Announces Reverse Stock Split of Common Stock
BU
Agenus : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
Agenus: Q4 Earnings Snapshot
AQ
Agenus Reports Fourth Quarter and Full Year 2023 Results
BU
Agenus Announces Preclinical Data on BMS-986442 at AACR 2024
AQ
Agenus Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
BU
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AGEN Stock
  4. News Agenus Inc.
  5. Press Releases